Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Medtronic plc (NYSE:MDT - Get Rating) - Equities research analysts at Jefferies Financial Group issued their FY2023 EPS estimates for shares of Medtronic in a research report issued to clients and investors on Tuesday, October 11th. Jefferies Financial Group analyst M. Taylor forecasts that the medical technology company will post earnings per share of $5.53 for the year. Jefferies Financial Group has a "Hold" rating and a $87.00 price objective on the stock. The consensus estimate for Medtronic's current full-year earnings is $5.53 per share. Jefferies Financial Group also issued estimates for Medtronic's FY2024 earnings at $5.78 EPS and FY2025 earnings at $6.21 EPS.

Medtronic (NYSE:MDT - Get Rating) last posted its earnings results on Tuesday, August 23rd. The medical technology company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.01. The firm had revenue of $7.37 billion during the quarter, compared to analyst estimates of $7.20 billion. Medtronic had a net margin of 16.75% and a return on equity of 13.64%. During the same period in the previous year, the firm earned $1.41 EPS.

Several other equities research analysts have also commented on the stock. Stifel Nicolaus cut their price target on shares of Medtronic from $125.00 to $105.00 in a report on Monday, July 18th. Citigroup cut their price target on shares of Medtronic from $110.00 to $108.00 in a report on Wednesday, October 5th. Morgan Stanley cut their price target on shares of Medtronic from $101.00 to $97.00 and set an "equal weight" rating for the company in a report on Tuesday. Mizuho initiated coverage on shares of Medtronic in a research note on Wednesday. They set a "buy" rating and a $100.00 target price on the stock. Finally, StockNews.com initiated coverage on shares of Medtronic in a research note on Wednesday. They set a "buy" rating on the stock. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $109.39.Medtronic Price Performance

Shares of NYSE MDT opened at $83.50 on Friday. The firm has a market cap of $110.98 billion, a PE ratio of 21.58, a PEG ratio of 1.82 and a beta of 0.76. The firm has a fifty day moving average of $88.18 and a 200 day moving average of $95.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.23 and a current ratio of 1.58. Medtronic has a one year low of $79.44 and a one year high of $128.32. Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Forum Financial Management LP purchased a new position in shares of Medtronic in the fourth quarter valued at approximately $991,000. Wulff Hansen & CO. purchased a new position in shares of Medtronic in the fourth quarter valued at approximately $563,000. Sequoia Financial Advisors LLC boosted its stake in shares of Medtronic by 1,160.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 81,933 shares of the medical technology company's stock valued at $8,476,000 after purchasing an additional 75,431 shares during the period. Byrne Asset Management LLC purchased a new position in shares of Medtronic in the fourth quarter valued at approximately $34,000. Finally, Tyler Stone Wealth Management acquired a new stake in Medtronic in the fourth quarter valued at approximately $363,000. Hedge funds and other institutional investors own 79.81% of the company's stock. Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Friday, September 23rd will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.26%. The ex-dividend date is Thursday, September 22nd. Medtronic's dividend payout ratio (DPR) is presently 70.28%. About Medtronic (Get Rating)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.See AlsoGet a free copy of the StockNews.com research report on Medtronic (MDT)Delta Air Lines Looks Ready To Take OffDoes the Zillow Stock Forecast Hint Toward a Turnaround?The Rally in Walgreen’s Boots Alliance May be Short LivedWill MGM Resorts Rise to the Top of the Casino Food Chain? Does Short Selling In AMC Mean The Stock Is A Horror Movie?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Brian Mulberry brings three large-cap ideas today and discusses why one utility may have potential beyond the traditional role of a dividend payer

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.